MedPath

Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use - RCT

Not Applicable
Recruiting
Conditions
Pregnancy
Interventions
Behavioral: Fitbit Only
Behavioral: LPA+Fitbit Intervention
Registration Number
NCT06239701
Lead Sponsor
Butler Hospital
Brief Summary

The overall goal of this pilot study is to develop and preliminarily evaluate an LPA intervention designed to reduce cannabis use during pregnancy.

Detailed Description

In the pilot RCT, we will recruit 50 women between 12-22 weeks gestation from an established network of prenatal clinics, and randomly assign eligible women to either a: 1) LPA+Fitbit intervention or 2) Fitbit Only control condition. Similar to our prior trials with pregnant women, the intervention period will be 12 weeks in duration during pregnancy, with follow-ups extending to the end of pregnancy and into the postpartum period. Major assessments will occur at baseline, end of treatment (EOT), and 4 weeks postpartum; we will also conduct brief phone surveys at three points in between the larger assessments. Participants will complete a 7-day period of accelerometry and urine toxicology screens following each major assessments. Birth record abstractions to collect information about specific outcomes (pre-term delivery, low birth weight) will be conducted by trained staff at one month post-birth.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
50
Inclusion Criteria
  1. women 18+ years of age
  2. 12-25 weeks gestation with a healthy singleton pregnancy
  3. medically-cleared by their prenatal provider for moderate intensity physical activity
  4. self-report of cannabis use at least once/week in the 3 months prior to the current pregnancy and desire to not engage in prenatal CU
  5. current psychological distress as defined by Edinburgh Postnatal Depression Scale score >7 and/or Generalized Anxiety Disorder 7 score >5)
  6. English-speaking
  7. owns a smartphone to enable use of the Fitbit app
  8. current physical activity level does not meet public health recommendations (less than 150 minutes/week moderate intensity physical activity for the past 3 months)
  9. expresses interest in reducing or discontinuing CU
Exclusion Criteria
  1. current DSM-5 diagnosis of moderate/severe substance use disorder other than cannabis use disorder or nicotine use disorder
  2. use of illicit substances in the last 3 months (other than cannabis)
  3. acute psychotic symptoms
  4. current or recent suicidality or homicidality
  5. current anorexia or bulimia
  6. current cognitive impairment
  7. physical or medical problems that would not allow safe participation in moderate intensity physical activity
  8. has plan to relocate away from the geographic area during the study intervention or assessment period
  9. recently started a new form of mental health or substance use treatment within the past 4 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Only FitbitFitbit OnlyThe Fitbit Only condition will include 3 components: 1. In-person Fitbit Orientation. 2. Fitbit Activity Tracker. 3. Brief Telephone Check-ins.
LPA and FitbitLPA+Fitbit InterventionThe 12-week LPA+Fitbit intervention consists of 3 components: 1. In-Person LPA+Fitbit Orientation 2. Telephone PA counseling sessions. 3. Fitbit activity tracker.
Primary Outcome Measures
NameTimeMethod
Activity Minutes/DayBaseline to 12-week endpoint

objectively-measured

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 1Baseline to 12-week endpoint

Self-reported cannabis use questionnaire -factor 1: daily sessions

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 4Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 4: Marijuana quantity

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 5Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 5: Concentrate quantity

Steps/dayBaseline to 12-week endpoint

objectively-measured

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 2Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 2: frequency

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 3Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 3: age of onset

The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 6Baseline to 12-week endpoint

Self-reported cannabis use questionnaire - factor 6: Edibles quantity

Urine Toxicology ScreenBaseline to 12-week endpoint

Objective screening for use of cannabis via measurement of THC in urine samples

Timeline Follow-back (TLFB)Baseline to 12-week endpoint

Interviewer-administered assessment of use of cannabis, alcohol, tobacco, and other drugs

International Physical Activity QuestionnaireBaseline to 12-week endpoint

self-report measure of physical activity including minutes/week spent walking, engaging in moderate physical activity, and engaging in vigorous physical activity

Secondary Outcome Measures
NameTimeMethod
Marijuana Self-Efficacy QuestionnaireBaseline to 12-week endpoint

Self-report measure of efficacy for cannabis abstinence; Scores range from 0-100, with higher scores indicating greater use of strategies to reduce marijuana consumption.

Generalized Anxiety Disorder -7Baseline to 12-week endpoint

Self-report measure of anxiety severity; scores range from 0-21, with higher scoring indicating more anxiety

Brief COPEBaseline to 12-week endpoint

Self-report measure of use of coping strategies; includes 14 2-item scales, each ranging from 2-8. Higher scores indicate increased utilization of a coping strategy.

Edinburgh Postnatal Depression ScreenBaseline to 12-week endpoint

Self-report measure of depression severity; scores range from 0-30, with higher scores indicating higher depression

Trial Locations

Locations (1)

Butler Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath